A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020–February 2021
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Social inequalities affect the COVID-19 burden and vaccine uptake. The aim of this study was to explore inequalities in the incidence and mortality rate of SARS-CoV-2 infection and vaccine uptake in various sociodemographic and population group strata in Israel. METHODS: We analysed nationwide publicly available, aggregated data on PCR-confirmed SARS-CoV-2 infections and COVID-19 deaths between March 2020 and February 2021, as well as the first three months of COVID-19 immunisation according to sociodemographics, including population group and residential socioeconomic status (SES). We computed incidence and mortality rates of COVID-19. Comparisons between towns with predominantly Arab, ultra-Orthodox Jewish (the minorities), general Jewish populations, and according to SES, were conducted using generalised linear models with negative binomial distribution. FINDINGS: Overall, 774,030 individuals had SARS-CoV-2 infection (cumulative incidence 84•5 per 1,000 persons) and 5687 COVID-19 patients had died (mortality rate 62•8 per 100,000 persons). The highest mortality rate was found amongst the elderly. Most (>75%) individuals aged 60 years or above have been vaccinated with BNT162b2 vaccine. The risk of SARS-CoV-2 infection was higher in towns with predominantly Arab and ultra-Orthodox Jewish populations than in the general Jewish population, and in low SES communities. COVID-19 mortality rate was highest amongst Arabs. Conversely, vaccine uptake was lower amongst Arab and ultra-Orthodox Jewish populations and low SES communities. INTERPRETATION: Ethnic and religious minorities and low SES communities experience substantial COVID-19 burden, and have lower vaccine uptake, even in a society with universal accessibility to healthcare. Quantifying these inequalities is fundamental towards reducing these gaps, which imposes a designated apportion of resources to adequately control the pandemic. FUNDING: No external funding was available for this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“On December 19, 2020, Israel introduced the BNT162b2 mRNA vaccine [22] in a vigorous immunisation campaign.”
Chu, D. K., Akl, E. A., Duda, S., Solo, K., Yaacoub, S., Schünemann, H. J., Chu, D. K., Akl, E. A., El-harakeh, A., Bognanni, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31142-9 · Cited by 3,843
A global survey of potential acceptance of a COVID-19 vaccine
Lazarus, J. V., Ratzan, S. C., Palayew, A., Gostin, L. O., Larson, H. J., Rabin, K., Kimball, S., & El-Mohandes, A. (2021) · Nature Medicine · doi:10.1038/s41591-020-1124-9 · Cited by 2,904 · cited 1×
“Improving trust in policy makers is essential to achieving compliance [42], therefore working with local community leaders should be given a high priority and the inclusion of professional representatives of minority groups should be an integral part of decision-making [38].”
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 2×
“A real-world study from Israel showed high BNT162b2 vaccine effectiveness [44] during a period when the UK variant was circulating in Israel, thus we anticipate that the vaccine will provide protection, although the duration of protection has yet to be determined and new vaccine generation might be needed.”
Ranking the effectiveness of worldwide COVID-19 government interventions
Haug, N., Geyrhofer, L., Londei, A., Dervic, E., Desvars-Larrive, A., Loreto, V., Pinior, B., Thurner, S., & Klimek, P. (2020) · Nature Human Behaviour · doi:10.1038/s41562-020-01009-0 · Cited by 1,412 · cited 1×
“Since then, compelling evidence has accumulated indicating that adequate face mask wearing is associated with significant protection against SARSCoV-2 infection, as well as physical distancing [34,35].”
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
CMMID COVID-19 Working Group, Davies, N. G., Jarvis, C. I., Edmunds, W. J., Jewell, N. P., Diaz-Ordaz, K., & Keogh, R. H. (2021) · Nature · doi:10.1038/s41586-021-03426-1 · Cited by 921 · cited 1×
“7 (UK) variant which is highly transmissible and causes more severe disease than previously known variants [45].”
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728 · cited 1×
“7 lineage following vaccination with BNT162b2 vaccine has been demonstrated [46].”
Association of Social and Demographic Factors with COVID-19 Incidence and Death Rates in the US
Karmakar, M., Lantz, P. M., & Tipirneni, R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.36462 · Cited by 580 · cited 3×
“For example, studies from the United States showed that racial/ ethnic minority status, SES and household characteristics were related to COVID-19 incidence and mortality rates [4,6].”
Atchison, C., Bowman, L. R., Vrinten, C., Redd, R., Pristerà, P., Eaton, J., & Ward, H. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043577 · Cited by 379 · cited 1×
“This is likely due to differences between the age groups in risk perception and adherence to risk mitigation measures [28]; young people commonly have a low personal risk perception of COVID-19 and thus tend to adhere less to preventive measures [28-30].”
Sex and age differences in COVID-19 mortality in Europe
Ahrenfeldt, L. J., Otavova, M., Christensen, K., & Lindahl-Jacobsen, R. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-020-01793-9 · Cited by 160 · cited 2×
“Similar findings were reported in other countries [31].”
Cited by
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114255 · Cited by 1,169
Waning Immunity after the BNT162b2 Vaccine in Israel
Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Haas, E. J., Milo, R., Alroy-Preis, S., Ash, N., & Huppert, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114228 · Cited by 1,034
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
(2022) · doi:10.1056/nejmoa2201570 · Cited by 376
Metadata
- Authors
- Muhsen, K., Na'aminh, W., Lapidot, Y., Goren, S., Amir, Y., Perlman, S., Green, M. S., Chodick, G., & Cohen, D.
- Venue
- The Lancet Regional Health - Europe
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 7
- Pages
- 100130
- ISSN
- 2666-7762 (ISSN-L)
- OpenAlex
- W3166394728
- Cited by
- 62
- References
- 10
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020–February 2021. https://app.cochat.ai/papers/10.1016/j.lanepe.2021.100130
- The paper
- Muhsen, K., Na'aminh, W., Lapidot, Y., Goren, S., Amir, Y., Perlman, S., Green, M. S., Chodick, G., & Cohen, D. (2021). A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020–February 2021. The Lancet Regional Health - Europe. https://doi.org/10.1016/j.lanepe.2021.100130
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.